COR vs. PFE: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at COR and PFE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | COR | PFE |
|---|---|---|
| Company Name | Cencora, Inc. | Pfizer Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 70.68 billion USD | 145.01 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | April 4, 1995 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of COR and PFE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | COR | PFE |
|---|---|---|
| 5-Day Price Return | -0.74% | 2.75% |
| 13-Week Price Return | 23.60% | -0.32% |
| 26-Week Price Return | 29.73% | 9.58% |
| 52-Week Price Return | 44.79% | -6.21% |
| Month-to-Date Return | 7.14% | 1.66% |
| Year-to-Date Return | 61.09% | -5.54% |
| 10-Day Avg. Volume | 1.79M | 126.04M |
| 3-Month Avg. Volume | 1.39M | 58.66M |
| 3-Month Volatility | 22.77% | 28.86% |
| Beta | 0.65 | 0.43 |
Profitability
Return on Equity (TTM)
COR
125.17%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
COR’s Return on Equity of 125.17% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
PFE
10.92%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
PFE’s Return on Equity of 10.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
COR
0.48%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
Falling into the lower quartile for the Health Care Providers & Services industry, COR’s Net Profit Margin of 0.48% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
PFE
15.65%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
PFE’s Net Profit Margin of 15.65% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
COR
0.81%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
COR’s Operating Profit Margin of 0.81% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
PFE
16.52%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
PFE’s Operating Profit Margin of 16.52% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | COR | PFE |
|---|---|---|
| Return on Equity (TTM) | 125.17% | 10.92% |
| Return on Assets (TTM) | 2.14% | 4.70% |
| Net Profit Margin (TTM) | 0.48% | 15.65% |
| Operating Profit Margin (TTM) | 0.81% | 16.52% |
| Gross Profit Margin (TTM) | 3.51% | 74.95% |
Financial Strength
Current Ratio (MRQ)
COR
0.90
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
COR’s Current Ratio of 0.90 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
PFE
1.28
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
PFE’s Current Ratio of 1.28 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
COR
4.38
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.38, COR operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
PFE
0.67
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
PFE’s Debt-to-Equity Ratio of 0.67 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
COR
8.75
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
COR’s Interest Coverage Ratio of 8.75 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
PFE
7.89
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
PFE’s Interest Coverage Ratio of 7.89 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | COR | PFE |
|---|---|---|
| Current Ratio (MRQ) | 0.90 | 1.28 |
| Quick Ratio (MRQ) | 0.54 | 0.97 |
| Debt-to-Equity Ratio (MRQ) | 4.38 | 0.67 |
| Interest Coverage Ratio (TTM) | 8.75 | 7.89 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
COR
0.62%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Yield of 0.62% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
PFE
6.72%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 6.72%, PFE offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
COR
22.69%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Payout Ratio of 22.69% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
PFE
98.75%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
PFE’s Dividend Payout Ratio of 98.75% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | COR | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.62% | 6.72% |
| Dividend Payout Ratio (TTM) | 22.69% | 98.75% |
Valuation
Price-to-Earnings Ratio (TTM)
COR
45.34
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
A P/E Ratio of 45.34 places COR in the upper quartile for the Health Care Providers & Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
PFE
14.69
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
PFE’s P/E Ratio of 14.69 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
COR
0.22
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, COR’s P/S Ratio of 0.22 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
PFE
2.30
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
PFE’s P/S Ratio of 2.30 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
COR
34.68
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
At 34.68, COR’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
PFE
1.46
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
PFE’s P/B Ratio of 1.46 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | COR | PFE |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 45.34 | 14.69 |
| Price-to-Sales Ratio (TTM) | 0.22 | 2.30 |
| Price-to-Book Ratio (MRQ) | 34.68 | 1.46 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.54 | 12.47 |